Candel Therapeutics (CADL) , a clinical-stage oncology company, is focused on developing two novel therapeutics, CAN-2409 and CAN-3110, to treat a variety of cancer indications.The company’s most advanced product candidate, CAN-2409, is an investigational adenovirus immunotherapy candidate that is being developed in separate mid to late-stage studies across three different types of cancer, including, prostate cancer, non-small cell lung cancer (NSCLC) and pancreatic cancer.On the other hand, CAN-3110, Cande ...